Attached files
| file | filename |
|---|---|
| EX-4.9 - FORM OF WARRANT FOR OFFERING - AYTU BIOPHARMA, INC | fs12018a1ex4-9_aytubio.htm |
| EX-3.9 - FORM OF CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SER - AYTU BIOPHARMA, INC | fs12018a1ex3-9_aytubio.htm |
| EX-5.1 - OPINION OF DORSEY & WHITNEY LLP - AYTU BIOPHARMA, INC | fs12018a1ex5-1_aytubio.htm |
| EX-1.1 - FORM OF UNDERWRITING AGREEMENT - AYTU BIOPHARMA, INC | fs12018a1ex1-1_aytubio.htm |
| S-1/A - AMENDMENT NO. 1 TO REGISTRATION STATEMENT - AYTU BIOPHARMA, INC | fs12018a1_aytubioscience.htm |
| EX-4.10 - FORM OF REPRESENTATIVE'S WARRANT - AYTU BIOPHARMA, INC | fs12018a1ex4-10_aytubio.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the inclusion in this Registration Statement (No. 333-227243) on Form S-1 and related prospectus of Aytu BioScience, Inc. (the “Company”) of our report dated September 6, 2018, with respect to the consolidated balance sheets of the Company as of June 30, 2018 and 2017, and the related consolidated statements of operations, stockholders’ deficit, and cash flows for the years then ended. We also consent to the reference to our firm under the heading “Experts” in the Registration Statement and prospectus.
Our report dated September 6, 2018 contains an explanatory paragraph that states that the Company's recurring losses from operations and accumulated deficit raise substantial doubt about the Company's ability to continue as a going concern, as discussed in Note 3 to the consolidated financial statements. The consolidated financial statements do not include any adjustments that might result from the outcome of that uncertainty.
/s/ EKS&H LLLP
Denver, Colorado
September 25, 2018